Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

Investors of Poshmark Stock Encouraged to Contact Kehoe Law Firm, P.C. - Breach of Fiduciary Duties Investigation Regarding NAVER's Buyout of POSH

11:15 am ET November 21, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 21, 2022 - Kehoe Law Firm, P.C. is investigating whether the directors of Poshmark, Inc. ("Poshmark") (NASDAQ:POSH) breached their fiduciary duties in approving a merger with NAVER Corporation ("NAVER") for inadequate consideration.

Kehoe Law Firm, P.C., Monday, November 21, 2022, Press release picture

The investigation concerns whether Poshmark's board of directors failed to maximize the value of Poshmark for the benefit of Poshmark's shareholders in connection with its announced merger with NAVER, in breach of their fiduciary duties to Poshmark's shareholders, and whether Poshmark's shareholders have suffered damages as a result.

On October 3, 2022, Poshmark announced it had reached an agreement to be bought out by NAVER for $17.90 per share. The transaction is valued at approximately $1.2 billion.

POSHMARK SHAREHOLDERS ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR POSHMARK HOLDINGS.

OWNERS OF POSHMARK STOCK ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO DISCUSS THE INVESTIGATION AND FOR A FREE, NO-OBLIGATION EVALUATION OF POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff-side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

SOURCE: Kehoe Law Firm, P.C.





View source version on accesswire.com:

https://www.accesswire.com/727550/Investors-of-Poshmark-Stock-Encouraged-to-Contact-Kehoe-Law-Firm-PC--Breach-of-Fiduciary-Duties-Investigation-Regarding-NAVERs-Buyout-of-POSH



comtex tracking

COMTEX_419409213/2457/2022-11-21T11:15:51

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.